strattera
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.00 | $40.05 (0%) | 🛒 Add to cart |
| 20 | $2.25 | $80.09 $45.05 (44%) | 🛒 Add to cart |
| 30 | $1.67 | $120.14 $50.06 (58%) | 🛒 Add to cart |
| 60 | $0.92 | $240.28 $55.06 (77%) | 🛒 Add to cart |
| 90 | $0.67 | $360.42 $60.07 (83%) | 🛒 Add to cart |
| 120 | $0.58 | $480.56 $70.08 (85%) | 🛒 Add to cart |
| 180 | $0.56 | $720.84 $100.12 (86%) | 🛒 Add to cart |
| 270 | $0.54 | $1081.26 $145.17 (87%) | 🛒 Add to cart |
| 360 | $0.50
Best per pill | $1441.69 $180.21 (88%) | 🛒 Add to cart |
| Product dosage: 18mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.51 | $45.05 (0%) | 🛒 Add to cart |
| 20 | $2.50 | $90.11 $50.06 (44%) | 🛒 Add to cart |
| 30 | $1.84 | $135.16 $55.06 (59%) | 🛒 Add to cart |
| 60 | $1.17 | $270.32 $70.08 (74%) | 🛒 Add to cart |
| 90 | $1.11 | $405.47 $100.12 (75%) | 🛒 Add to cart |
| 120 | $1.08 | $540.63 $130.15 (76%) | 🛒 Add to cart |
| 180 | $1.00 | $810.95 $180.21 (78%) | 🛒 Add to cart |
| 270 | $0.93 | $1216.42 $250.29 (79%) | 🛒 Add to cart |
| 360 | $0.88
Best per pill | $1621.90 $315.37 (81%) | 🛒 Add to cart |
| Product dosage: 25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.01 | $50.06 (0%) | 🛒 Add to cart |
| 20 | $2.75 | $100.12 $55.06 (45%) | 🛒 Add to cart |
| 30 | $2.00 | $150.18 $60.07 (60%) | 🛒 Add to cart |
| 60 | $1.50 | $300.35 $90.11 (70%) | 🛒 Add to cart |
| 90 | $1.45 | $450.53 $130.15 (71%) | 🛒 Add to cart |
| 120 | $1.33 | $600.70 $160.19 (73%) | 🛒 Add to cart |
| 180 | $1.11 | $901.05 $200.23 (78%) | 🛒 Add to cart |
| 270 | $1.00 | $1351.58 $270.32 (80%) | 🛒 Add to cart |
| 360 | $0.83
Best per pill | $1802.11 $300.35 (83%) | 🛒 Add to cart |
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $6.01 | $60.07 (0%) | 🛒 Add to cart |
| 20 | $3.50 | $120.14 $70.08 (42%) | 🛒 Add to cart |
| 30 | $3.67 | $180.21 $110.13 (39%) | 🛒 Add to cart |
| 60 | $3.34 | $360.42 $200.23 (44%) | 🛒 Add to cart |
| 90 | $2.89 | $540.63 $260.30 (52%) | 🛒 Add to cart |
| 120 | $2.50 | $720.84 $300.35 (58%) | 🛒 Add to cart |
| 180 | $2.17 | $1081.26 $390.46 (64%) | 🛒 Add to cart |
| 270 | $1.67 | $1621.90 $450.53 (72%) | 🛒 Add to cart |
| 360 | $1.39
Best per pill | $2162.53 $500.59 (77%) | 🛒 Add to cart |
Synonyms | |||
Strattera represents one of the more interesting pharmacological approaches in our ADHD toolkit – it’s the first non-stimulant medication specifically approved for attention-deficit/hyperactivity disorder. Unlike the methylphenidates and amphetamines that dominate this space, Strattera works through norepinephrine reuptake inhibition, which gives us a completely different mechanism to offer patients who can’t tolerate stimulants or have comorbid conditions that make stimulants problematic.
1. Introduction: What is Strattera? Its Role in Modern Medicine
Strattera (atomoxetine hydrochloride) occupies a unique position in ADHD pharmacotherapy as the first FDA-approved non-stimulant for this condition. When we first started using it back in 2002, many of us were skeptical – could a non-stimulant really deliver meaningful results for ADHD? What we’ve learned over two decades is that Strattera provides an essential alternative for patients who can’t take stimulants due to substance abuse concerns, cardiovascular issues, or significant anxiety comorbidities.
The medication comes in capsule form with various strengths – 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, and 100mg – allowing for careful titration. Unlike stimulants, it’s not a controlled substance, which removes many of the prescribing barriers and monitoring requirements that complicate stimulant treatment.
I remember when we first added Strattera to our hospital formulary – there was quite a debate among our department about whether it was worth the cost given the established efficacy of stimulants. Dr. Chen argued passionately that we needed alternatives for our patients with comorbid anxiety disorders, while our department chair was concerned about the slower onset of action. Both were right, as it turned out.
2. Key Components and Pharmaceutical Profile
Atomoxetine hydrochloride is the active pharmaceutical ingredient in Strattera, formulated as a selective norepinephrine reuptake inhibitor. The hydrochloride salt improves solubility and bioavailability, which is particularly important given its absorption characteristics.
The pharmacokinetics are worth understanding in detail – Strattera is well-absorbed orally regardless of food intake, which is convenient for patients. But here’s the crucial part that many clinicians miss: it undergoes extensive metabolism via cytochrome P450 2D6 (CYP2D6). This creates significant variability in plasma concentrations between patients. Poor metabolizers (about 7% of Caucasians and 2% of African Americans) can have atomoxetine concentrations up to five times higher than extensive metabolizers.
We learned this the hard way with one of my early patients – a 32-year-old woman we’ll call Sarah who developed significant hypertension and tachycardia on what should have been a standard dose. Genetic testing later confirmed she was a poor metabolizer. This experience taught me to always start low and go slow, especially when family history is unclear.
The capsules contain pregelatinized starch and dimethicone among other inactive ingredients, but the key point is the delayed-release formulation that provides relatively stable plasma concentrations throughout the day.
3. Mechanism of Action: Scientific Substantiation
Strattera’s mechanism is fundamentally different from stimulants – it selectively inhibits presynaptic norepinephrine transporters in the prefrontal cortex without directly affecting dopamine transporters in the reward centers of the brain. This is why it lacks the abuse potential of stimulants.
The norepinephrine system in the prefrontal cortex modulates executive functions – attention, working memory, behavioral inhibition. By increasing norepinephrine availability in this specific brain region, Strattera enhances signaling without creating the widespread activation characteristic of stimulants.
I often explain it to residents this way: if stimulants are like turning on all the lights in a house, Strattera is like installing a brighter bulb in just the study where you need to focus. The effect is more targeted, though sometimes less powerful for certain symptoms.
What surprised me early on was how the therapeutic effects build gradually over several weeks. Unlike stimulants that work within hours, Strattera requires patience from both clinician and patient. I had one teenager – let’s call him Mark – whose parents almost discontinued treatment after two weeks because they saw no improvement. We persisted, and by week 6, his teacher reports showed remarkable improvement in classroom attention and homework completion.
4. Indications for Use: What is Strattera Effective For?
Strattera for ADHD in Children and Adolescents
The evidence for pediatric ADHD is robust across multiple randomized controlled trials. Improvement typically appears in attention, hyperactivity, and impulsivity domains, though the magnitude of effect is generally somewhat less than with stimulants. The key advantage is the 24-hour coverage without rebound effects.
Strattera for Adult ADHD
Many clinicians don’t realize Strattera has solid evidence for adult ADHD – in fact, some studies show particularly good results for the executive function deficits that often persist into adulthood. The effect on emotional dysregulation in adults with ADHD has been particularly impressive in my practice.
Strattera for ADHD with Comorbid Anxiety
This is where Strattera really shines clinically. Unlike stimulants that can exacerbate anxiety, Strattera often improves both conditions simultaneously. I’ve had numerous patients with comorbid generalized anxiety disorder who couldn’t tolerate stimulants but did exceptionally well on Strattera.
Off-label Uses
We’ve found some benefit for treatment-resistant depression as an augmenting agent, particularly when fatigue and concentration problems are prominent. There’s emerging evidence for its use in traumatic brain injury with attention deficits, though this remains investigational.
5. Instructions for Use: Dosage and Course of Administration
Dosing requires careful consideration of age, weight, and metabolic status. For children and adolescents up to 70 kg, we start at 0.5 mg/kg and gradually increase to a target of 1.2 mg/kg. For those over 70 kg and adults, initial dosing is 40 mg daily, increasing after minimum of 3 days to 80 mg, and potentially to 100 mg if needed.
| Population | Initial Dose | Target Dose | Maximum Dose | Administration |
|---|---|---|---|---|
| Children <70 kg | 0.5 mg/kg | 1.2 mg/kg | 1.4 mg/kg | Once daily or divided |
| Children >70 kg & Adults | 40 mg | 80 mg | 100 mg | Once daily or divided |
The divided dosing (morning and late afternoon/early evening) can help minimize side effects while maintaining coverage into the evening hours for homework and family activities.
I learned about the importance of evening dosing from a 16-year-old patient – let’s call her Jessica – who was doing well academically but having significant family conflicts during evening hours. Splitting her dose eliminated this problem entirely.
6. Contraindications and Drug Interactions
Absolute contraindications include narrow-angle glaucoma and use within 2 weeks of MAO inhibitors. Relative contraindications include significant hypertension, tachycardia, cardiovascular disease, and severe liver impairment.
The drug interaction profile is crucial – CYP2D6 inhibitors like paroxetine, fluoxetine, and quinidine can significantly increase atomoxetine levels. I once managed a patient on fluoxetine for OCD who developed marked hypertension and urinary retention when we added Strattera – we had to reduce the Strattera dose by 60% to achieve safety and efficacy.
Common side effects include decreased appetite, nausea, fatigue, and mild increases in heart rate and blood pressure. The gastrointestinal effects typically diminish after several weeks, but I always warn patients about this temporary adjustment period.
7. Clinical Studies and Evidence Base
The evidence base for Strattera is substantial – over 50 randomized controlled trials and numerous long-term extension studies. The landmark MTA study extensions showed maintained efficacy over 24 months, which addresses the chronic nature of ADHD treatment.
What’s particularly compelling is the data on quality of life measures – multiple studies show improvements in family functioning, academic performance, and social functioning that go beyond symptom reduction.
The effect sizes for Strattera in ADHD treatment typically range from 0.6 to 0.8, compared to 0.8 to 1.0 for stimulants. But these numbers don’t capture the individual variation – I’ve had patients who responded minimally to multiple stimulants but had dramatic improvements with Strattera.
One of my most memorable cases was a 45-year-old attorney – we’ll call him David – who had failed multiple stimulants due to anxiety and insomnia. On Strattera, not only did his concentration improve, but his wife reported that their marriage was better because he was finally “present” during conversations.
8. Comparing Strattera with Similar Products and Choosing Appropriate Therapy
The decision between Strattera and stimulants isn’t about which is “better” but which is better for a particular patient. Stimulants generally have faster onset and slightly greater efficacy for core ADHD symptoms, but Strattera offers 24-hour coverage without abuse potential and often better tolerability in comorbid anxiety.
When I’m consulting with families, I frame it as a risk-benefit discussion – if substance abuse concerns, anxiety disorders, or tic disorders are present, Strattera often becomes the first-line choice despite the slower onset of action.
The cost consideration has improved with generic availability, though insurance coverage still varies significantly. The need for prior authorizations remains a barrier in many healthcare systems.
9. Frequently Asked Questions (FAQ) about Strattera
How long does Strattera take to work?
Therapeutic effects typically begin within 2-4 weeks, with maximal benefit at 6-12 weeks. This delayed onset requires patience and careful patient education.
Can Strattera be combined with stimulant medications?
There’s limited evidence for combination therapy, though some specialists use this approach for partial responders. I’ve used low-dose Strattera with moderate-dose stimulants in treatment-resistant cases with careful monitoring.
What monitoring is required during Strattera treatment?
We check height and weight in children every 3-6 months, with blood pressure and heart rate monitoring at each dose adjustment and periodically during maintenance therapy.
Does Strattera cause emotional blunting?
Some patients report reduced emotional reactivity, which can be beneficial for emotional dysregulation but problematic if excessive. Dose adjustment usually manages this effectively.
10. Conclusion: Validity of Strattera Use in Clinical Practice
After nearly twenty years of using Strattera in my practice, I’ve come to appreciate its unique role in our ADHD treatment arsenal. It’s not a replacement for stimulants, but an essential alternative that expands our ability to help diverse patient populations.
The slower onset requires managing expectations, and the side effect profile demands careful monitoring, but the benefits for appropriate patients are substantial and sustained.
What continues to surprise me is how some patients who’ve struggled for years with partial responses to stimulants find their “answer” with Strattera. Just last month, I saw a patient I’d started on Strattera eight years ago – now a successful college graduate – who told me it “changed everything” by giving him consistent focus without the rollercoaster of stimulant effects.
The development journey wasn’t smooth – I remember the early concerns about hepatotoxicity that led to the black box warning, and the debates about whether the cardiovascular effects were clinically significant. But the accumulated evidence and clinical experience have solidified Strattera’s place as a valuable tool in comprehensive ADHD management.
We’ve learned to identify the right candidates – those with comorbid anxiety, substance use concerns, or desire for 24-hour coverage – and to manage the expectations around the gradual onset of action. The key is recognizing that ADHD pharmacotherapy isn’t one-size-fits-all, and having Strattera available means we can offer truly personalized treatment approaches.
Looking back at my early skepticism, I now consider Strattera an indispensable part of our practice – not for everyone, but for the right patients, it makes all the difference.